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Abstract: 
Originating in the brain, glioblastoma (GBM) is a highly lethal and virtually incurable cancer, in 
large part because it readily develops resistance to treatments. While numerous studies have 
investigated mechanisms enabling GBM cells to evade chemotherapy-induced apoptosis, few 
have addressed how their surrounding extracellular matrix (ECM) acts to promote their survival. 
Here, we employed a biomaterial-based, 3D culture platform to investigate systematically how 
interactions between patient-derived GBM cells and the brain ECM promote resistance to 
alkylating chemotherapies — including temozolomide, which is used routinely in clinical practice. 
Scaffolds for 3D culture were fabricated from hyaluronic acid (HA) — a major structural and 
bioactive component of the brain ECM — and functionalized with the RGD (arginine-glycine-
aspartic acid) tripeptide to provide sites for integrin engagement. Data demonstrate that 
cooperative engagement of CD44, through HA, and integrin αV, through RGD, facilitates 
resistance to alkylating chemotherapies through co-activation of Src, which inhibited 
downstream expression of BCL-2 family pro-apoptotic factors. In sum, a bioengineered, 3D 
culture platform was used to gain new mechanistic insights into how ECM in the brain tumor 
microenvironment promotes resistance to chemotherapy and suggests potential avenues for the 
development of novel, matrix-targeted combination therapies designed to suppress 
chemotherapy resistance in GBM. 
Graphical Abstract: 
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Highlights: 
Hyaluronic acid (HA) and RGD-containing proteins in the extracellular matrix (ECM) interact with 
integrin and CD44 receptors, respectively, on patient-derived glioblastoma (GBM) cells to 
promote upregulation of Src in novel 3D hydrogel cultures. 
Matrix-mediated Src activation promotes invasive morphologies and deregulates expression of 
pro-apoptotic factors induced by chemotherapies in GBM. 
HA and adhesive proteins in the ECM protect GBM cells from chemotherapy-induced apoptosis.  
Combinatorial treatment with chemotherapy dasatinib, which inhibits Src phosphorylation, 
provides a promising strategy to overcome matrix mediated drug resistance in GBM. 
1. Introduction: 
Glioblastoma (GBM) is the most common, yet lethal, cancer originating in the central nervous 
system[1,2]. Its lethality stems from its robust resistance to treatment and aggressive infiltration 
of healthy tissue[1]. The alkylating chemotherapy temozolomide (TMZ) is routinely used as an 
adjuvant chemotherapy following surgical resection of tumors and post-surgery radiotherapy. 
Although less common than TMZ treatment, biodegradable wafers, which continuously deliver 
the alkylating chemotherapy agent carmustine (also known as BCNU), have also been used 
widely for GBM treatment. Unfortunately, even with treatment the median survival of GBM 
patients is only 12-15 months[3]. 
The important role of the extracellular matrix (ECM) in treatment resistance has been indicated 
in several cancers. For example, CD44 activation through hyaluronic acid (HA) has been 
reported to support cancer growth, resistance and metastasis[4–6]. Likewise, cell-adhesive 
proteins in the ECM, in particular those containing the integrin-binding RGD (arginine-glycine-
aspartic acid) motif, mediate downstream signaling pathways associated with cancer cell 
survival and invasion[7]. In GBM, elevated expression of the ECM components — including the 
glycosaminoglycan hyaluronic acid (HA) and several cell-adhesive proteins — and their 
corresponding cell surface receptors — CD44 and integrins, respectively — has been frequently 
reported to correspond with disease progression[7–10]. ECM engagement with either integrin or 
CD44 receptors has been reported to activate Src protein-tyrosine kinase (Src) in [11–13]. In 
sarcoma and ovarian cancer, Src has been observed as a modulator of treatment sensitivity, 
where its inhibition by dasatinib promoted chemotherapy-induced apoptosis[14,15]. In GBM, a 
number of studies have found correlations between Src hyper-activation and tumorigenesis, 
invasion and progression [11,12,15,16]. However, these previous studies were largely focused 
on elucidating the role of Src in GBM invasion and how Src activation may influence treatment 
response in GBM remains largely unknown.  
Despite a growing body of evidence indicating that ECM in the GBM tumor microenvironment 
facilitates therapeutic resistance, it has been a technical challenge to investigate the underlying 
mechanisms of this influence in a systematic and detailed manner. While in vivo studies can 
provide valuable information, the ubiquitous nature of most ECM components, and their 
respective receptors, throughout organ systems makes it difficult to isolate independent effects 
of specific ECM-tumor cell interactions on tumor behavior and necessitates the use of a 
simplified, ex vivo system. However, common approaches for experimental culture do not 
provide GBM cells with adequate microenvironmental support to preserve their physiology [17]. 
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For example, previous studies of cell-ECM interactions have relied heavily on non-specific 
adsorption of large ECM biomolecules, resulting in uncontrolled protein denaturation, onto two-
dimensional (2D) culture substrates with stiffness orders of magnitude harder than normal brain 
or tumor tissues[18]. Gliomasphere (GS) cultures, where GBM tumor spheroids are cultured in 
suspension have also been widely used[19]. While GS cultures provide a more realistic, 3D 
microenvironment for intercellular interactions than 2D monolayers, they do not provide any 
control over the surrounding ECM microenvironment, which includes biochemical and 
biomechanical features.  
Here, we employed hydrogel biomaterials that surround 3D cultured, patient-derived GBM cells 
with a bioengineered matrix composed of HA and integrin-binding sites based on the “RGD” 
adhesive tripeptide. As the mechanical microenvironment can also have profound effects on 
tumor cells[8,20], hydrogel matrices were designed to approximate the mechanical properties of 
native brain. Previously, we demonstrated that patient-derived GBM cells cultured in these 
tunable, 3D culture matrices better approximated responses to therapeutic inhibition of 
epidermal growth factor receptor (EGFR) observed in patient-matched, orthotopic xenografts 
than did patient-matched GS cultures [21]. Here, we used these hydrogel cultures to 
demonstrate that CD44-HA and integrin-RGD interactions act together to drive chemotherapy 
resistance. Furthermore, we have identified Src activation as a key signaling event mediating 
both chemotherapy resistance and invasive morphology. Finally, we demonstrate that ECM 
components act to protect GBM cells from chemotherapy-induced apoptosis through 
downstream, Src-mediated inhibition of BCL-2 family pro-apoptotic factors. 
2. Methods: 
All reagents were purchased from ThermoFisher unless otherwise stated. 
Fabrication of hydrogel matrices: Hyaluronic acid (HA, average molecular weight 700kDa, 
LifeCore Biomedical, Chaska, MN, USA) was thiolated (~5% of the repeating disaccharide 
units), as previously described[21,22]. Maleimide-terminated 4-arm polyethylene glycol (4-arm-
PEG-Mal, 20kDa) from Laysan Bio (Arab, AL, USA) was resuspended at 12.5mg/ml in 
phosphate buffered saline (PBS, MilliporeSigma, Temecula, CA, USA). L-Cysteine 
(MilliporeSigma) or RGD peptide (customized sequence N-Ac-GCGYGRGDSP-COOH from 
Genscript, Piscataway, NJ, USA) was reconstituted in PBS (2.81 mM), then mixed with 4-arm-
PEG-Mal solution at a 2:1 molar ratio to achieve 150 M of final concentration of peptide or L-
cysteine. Thiolated HA was dissolved at 13.3 mg/mL in 20 mM HEPES buffer and adjusted to 
around pH 7 before mixing with 5 mg/mL thiol-terminated 4-arm-poly ethylene glycol (4-arm-
PEG-SH, 20kDa, Laysan Bio, Arab, AL, USA) at a 3:1 volume ratio. Finally, an equal volume of 
4-arm-PEG-Mal solution was mixed with thiolated HA/4-arm-PEG-SH solution (total of 80 l) in 
a silicone mold (Grace Biolabs, Bend, OR, USA). 
Patient-derived GBM cell lines: GBM cell lines derived from patients (HK301, GBM6, GS024, 
and GS025) were used. HK301 was generously provided Dr. Harley Kornblum at UCLA and 
was collected in April 2010. GS024 and GS025 were collected in March 2015. GBM6 was 
collected in span of 1999-2006[23]. GS024, GS025 and HK301 were collected with approval 
and according to guidelines from the UCLA Institutional Review Board protocol 10-000655 [24]. 
HK301 cells were used between passages 15 and 25, GBM6 were used between passages 10 
and 15, and GS024 and GS025 were used between passages 4 and 9. All cell lines were 
verified through short tandem repeat analysis[25]. 
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Gliomasphere culture: GBM cells (50,000/mL) were cultured in suspension in DMEM/F12 with 
1x G21 (Gemini Bio-Products, West Sacramento, CA, USA), 1% penicillin/streptomycin, 50 
ng/mL epidermal growth factor (EGF) (PeproTech, Rocky Hill, NJ, USA), 20 ng/ml fibroblast 
growth factor-basic (FGF-2) (PeproTech), and 25 g/mL heparin (MilliporeSigma, St. Louis, MO, 
USA). Cultures were routinely tested for mycoplasma contamination (C7028, Thermo Fisher 
Scientific, Waltham, MA, USA). TrypLE Express (1 mL) was used to dissociate GS once they 
reached approximately 200 m in diameter. Dissociated cells were passed through a 70 m cell 
strainer to remove any remaining aggregates before re-seeding into suspension culture. To 
establish hydrogel cultures, dissociated, single cells were resuspended (1 million cells/mL) in 
approximately 12 mg/mL of peptide-modified PEG-maleimide solution prior to mixing the HA-
thiol/PEG-thiol solution to initiate crosslinking, which occurs rapidly at 37ºC. Cell culture medium 
was added to cover the hydrogel cultures 10 min. after mixing.  
Viral transduction: shCD44-2 pRRL was a gift from Bob Weinberg (Addgene Plasmid #19123). 
GIPZ Human ITGAV shRNA (Clone Id: V2LHS_133468) lentiviral vector glycerol stock was 
purchased from Dharmacon, Inc. (Lafayete, CO). Lentivirus was produced using the human 
embryonic kidney (HEK Lenti 293T) cell line (Takara Bio USA, Mountain View, CA). A third-
generation packaging system was used to produce the lentivirus[26]. Virus was added to cell 
culture in 6-well plate with multiplicity of infection of 2000. Fresh medium was replaced 24 hrs 
after infection. Cells were allowed to grow for another 48 hrs before encapsulation.  
Drug treatment:  Temozolomide (TMZ), carmustine, cilengitide, and dasatinib were purchased 
from MilliporeSigma. TMZ and dasatinib were prepared in DMSO at 100 mM and 10 mM, 
respectively. Carmustine was dissolved in ethanol at 100 mM, and cilengitide was in PBS at 
10mM. Final working concentrations of each compound were: 500 µM TMZ, 100 µM carmustine 
for the GBM6 cell line, 50 µM carmustine for all other cell lines, 100 nM dasatinib and 50 µM 
cilengitide. Working concentrations of TMZ and carmustine were determined by IC50 for each 
cell line. All vehicle groups in the treatment had equivalent amounts of DMSO, ethanol, or PBS 
added to culture media.  
Bioluminescence imaging of live cultures: GBM cells were transduced with lentivirus encoding 
for constitutive expression of firefly luciferase, as previously described[21]. D-luciferin (1 mM) 
was added to the culture medium 1 hr prior to imaging. Bioluminescence signal was imaged 
using an IVIS Illumina II (PerkinElmer, Waltham, MA, USA) with a 4-5 mins exposure. All 
readings are normalized to background intensity and area. Relative luminescence units (RLU), 
photon intensity corrected for background and noise of the detector, for experimental groups at 
each time point were normalized to RLU from samples in vehicle groups and RLU at day 0. 
Hydrogel culture cryopreservation, immunostaining, and imaging:  Hydrogel cultures were fixed 
in 4% para-formaldehyde (PFA) at 4oC overnight. The next day, the hydrogels were incubated 
serially in solutions with increasing concentrations of sucrose in PBS (5-20 wt%). On third day, 
the hydrogels were embedded in 20 wt% sucrose in O.C.T. and flash frozen in 2-methylbutane. 
Frozen samples were stored at -80oC until cryosectioning into 18 µm sections, as previously 
described[22]. The sections were fixed in 4% PFA for 10 min. and washed in tris-buffered saline 
(TBS) before blocking using 1% bovine serum albumin (BSA) and 5% normal donkey serum for 
1hr at room temperature. Primary antibodies, diluted in blocking buffer, were incubated with 
sections at 4oC overnight. The next day, the slides were washed in TBS. Appropriate secondary 
antibodies and Hoescht 33342 were diluted in TBS and incubated with sections at room 
temperature for 45 min. Finally, sections were washed in TBS and mounted with coverslips 
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using fluoromount G (Southern Biotech, Birmingham, AL, USA). All samples were imaged with 
Zeiss Axio-Observer microscope (Carl Zeiss, Oberkochen, Germany). All fluorescent images 
within the same comparison groups were imaged with same parameters, and all samples within 
each comparison group were prepared and processed together. For details on antibodies used, 
please see Supplementary Table 1.  
Western blotting: Hydrogel cultures were placed in 1.5 mL microcentrifuge tubes. 100 µL RIPA 
buffer with 1x protease/phosphatase inhibitors (MilliporeSigma) were incubated with the 
hydrogels on ice. A 1 mL syringe attached with 20G needle was used to homogenize the 
sample. The mixture was then incubated on ice for an additional 15 min. For GS cultures, 
dissociated cells were centrifuged at 500xg for 5 min. followed by resuspension with complete 
RIPA buffer with 1x protease/phosphatase inhibitors on ice, and the mixture was incubated on 
ice for 15 min. with occasional vortexing. All samples were centrifuged 14,000xg for 15 min. 
Supernatants were collected and 1:1 mixed with laemmli buffer with 5% 2-mercaptoethanol. 
SDS-PAGE was performed using a 12-well, 4-12% bis-tris gradient gel in a mini blot module 
under 1x MOPS buffer. Protein was transferred from the SDS-PAGE gel to a PVDF membrane 
in 1x transfer buffer under 20V for 100 min. Blots were blocked in 5% BSA in TBS with 0.1% 
tween (TBST) for 1hr at room temperature, and then incubated with primary antibodies diluted in 
blocking buffer at 4oC overnight. The next day, blots were washed with TBST, before incubating 
with secondary antibody diluted in 5% BSA in TBST for 1hr at room temperature. After 
additional washes in TBST, blots were incubated in Clarity Western ECL Substrates (Bio-Rad, 
Hercules, CA, USA) for 3 min. and imaged in MyECL Imager.  For the list of antibodies, 
information on working dilutions and expected molecular weights used in the study, please see 
Supplementary Table 1 For original chemiluminescence blot images marked with molecular 
weight ladders, please see Figure S1. 
Flow cytometry for analysis of proliferation: To measure percentage of cell population that has 
actively undergone proliferation, 5-ethynyl-2’deoxyuridine (EdU, 10µM, Abcam, Cambridge UK) 
was added to culture medium and incubated in 37oC for 2.5 hrs. Hydrogel or gliomasphere 
cultures were then placed in 1mL of TrypLE Express at 37 oC for 5 min. before adding 4 mL of 1% 
BSA in PBS to the reaction mixture. For hydrogel cultures, the mixture was passed through a 20 
G needles at least 8 times gently. Cell suspensions from both hydrogel and gliomapshere 
cultures then were filtered through a 70 µm cell strainer. An additional 5mL of 1% BSA in PBS 
was used to wash the cell strainer and collect any remaining cells. The mixture was centrifuged 
at 500 x g for 5 min., and the supernatant removed. The cell pellet was resuspended in 100 µL 
of 4% PFA and incubated for 15 min, before washing with 3 mL of 1%BSA in PBS. Fixed cells 
were permeabilized in 100 µL of 0.1% saponin (MilliporeSigma) in 1% BSA in PBS for 15 min., 
followed by an additional 500 µL of 100 mM sodium ascorbate, 2mM CuSO4 and 1µM Alexa 
Fluor 647 Azide in PBS for 30 min. in the dark. Finally, cells were washed with 3 mL of 0.1% 
saponin and 1% BSA in PBS and resuspended in 500 µL of washing buffer. Data were collected 
using Fortessa LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and were 
analyzed using FlowJo software. EdU positive cell population represents percentage of cells 
have gone through S phase of cell division during the 2.5 hr period of exposure to EdU in 
culture. 
Statistical Analysis: Statistical analysis was performed by using GraphPad Prism software (La 
Jolla, CA, USA). In most cases, student’s t test or ANOVA with Tukey’s post-hoc comparisons 
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were used to determine statistical significance. More details and any deviations from this 
procedure are provided in figure captions when applicable. 
3. Results: 
3.1 High HA scaffolds facilitate chemotherapy resistance 
We employed a 12-day treatment protocol where cells were exposed to two treatment cycles — 
3 days with drug followed by 3 days without — to approximate treatment cycles used for TMZ 
chemotherapy in clinical practice[27] (Fig. 1A). Drug response was observed in patient-derived 
GBM cells cultured in 3D hydrogels fabricated with either high (0.5% w/v) or low (0.1% w/v) HA 
content, as previously described[21]. After 12 days in culture HK301 cells formed spheroid 
aggregates with similar morphologies in both scaffold conditions without treatment (vehicle 
control) and high HA scaffolds wither treatment (TMZ or carmustine) (Fig. 1B). In contrast, cell 
aggregates were clearly smaller in low HA scaffolds with treatment. Growth kinetics of scaffold 
cultures tracked over time through bioluminescence imaging of a constitutively overexpressing 
luciferase reporter confirmed that HK301 cells in high HA hydrogels had grown significantly 
more than those in other conditions, starting at day 6 of the treatment scheme (Fig. 1C). No 
obvious differences in cell morphology or aggregation were observed with scaffold type or 
treatment for GBM6 cells (data not shown). The exact number of days before resistance was 
observed in GBM6 cultures were highly variable across independent experimental trails (Fig. 
S2A). However, quantification of the bioluminescence signal from treated cultures, normalized 
to that from untreated, at the end of the treatment on day 12 confirmed that both HK301 and 
GBM6 cells cultured in high HA hydrogels were less responsive to alkylating chemotherapies 
than those cultured in low HA content hydrogels or as GS (Fig. 1D).  
In clinical cases, a cycle of TMZ chemotherapy is typically defined as 5 days of treatment 
followed 23 days of not treatment, or “rest”[3].  During this “rest” period, tumors have the 
opportunity to recover, adapt and/or grow. Here, we applied 3 days of treatment followed by 3 
days of “rest”. During the first “rest” period (days 3-6), tumor cell cultures appeared to switch to 
a state that was less responsive to treatment with either TMZ or carmustine and average growth 
rates were more similar to untreated controls (Fig. 1C).  
3.2 Matrix HA interacts with CD44 to protect against chemotherapy-induced apoptosis  
To investigate the mechanism by which the HA-rich hydrogel scaffolds create a 
microenvironment that facilitates drug resistance, we first tested whether culture in hydrogels 
prevented DNA damage from exposure to chemotherapy agents. Using an EdU-based assay, 
we found that carmustine treatment reduced DNA incorporation (i.e., proliferation rate) in both 
high HA hydrogel and GS cultures as measured on the 3rd day of carmustine treatment (Fig. 2A; 
Fig. S2B). TMZ treatment had a similar cytostatic effect on cultures in high HA (Fig. S2C). 
When GS were treated with either drug, too few cells remained to perform reliable 
measurements of EdU incorporation via flow cytometry (data not shown). Although carmustine 
treatment attenuated cell proliferation in both hydrogel scaffold and GS cultures, proliferation in 
GS was essentially halted while some proliferation persisted in hydrogel cultures, prompting 
further investigation.  
Alkylating agents induce cell cycle arrest, eventually leading to programmed cell death, or 
apoptosis[28]. Thus, we suspected hydrogel-cultured cells may have gained resistance to the 
cytostatic effects of carmustine via reduced cytotoxicity. As predicted, when treated with 
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carmustine, relative expression of cleaved poly ADP ribose polymerase (cl-PARP), a marker for 
late-stage apoptosis, in HK301 cells was higher in GS than in high HA hydrogel cultures (Fig. 
2B). This comparison could not be made with GBM6 cells, as too many cells died with treatment 
to make it possible to collect lysate for Western blotting. By comparing cl-PARP expression in 
high and low HA hydrogel cultures of HK301 cells, we further confirmed that increased HA 
content led to a reduction in apoptosis (i.e., cl-PARP expression) in response to treatment (Fig. 
2C, Fig. S3A). To evaluate the contribution of the CD44 receptor to anti-apoptotic protection 
provided by the HA matrix, we repeated experiments with GBM cells transduced with shRNA to 
knockdown CD44 expression. Treatment-induced apoptosis increased significantly with the 
CD44 knockdown (Fig. 2D, Fig. S3B). No treatment (vehicle) controls confirmed that the CD44 
knockdown alone was not sufficient to induce cl-PARP expression.  
3.3 The RGD motif and HA synergistically protect against treatment-induced apoptosis  
The integrin-binding RGD motif is found in many ECM proteins, and cell adhesion through RGD 
has been reported to promote survival and invasion in GBM[29]. Our hydrogel system enables 
incorporation of ECM-mimetic peptides containing RGD to recapitulate cell-ECM interactions 
through which biochemical and biomechanical cues may be transduced [21,22]. After GBM cell 
encapsulation into RGD-incorporated hydrogels, the majority of cells displayed an invasive 
morphology resembling a multicellular, or collective, migration mode (Fig. 3A; Fig. S4). In 
contrast, cells remained as spheroid aggregates when cultured in hydrogels lacking the RGD 
motif. When treated with TMZ or carmustine, incorporation of RGD provided additional 
protection against apoptosis, significantly reducing cl-PARP expression over that in high HA 
scaffolds without RGD (Fig. 3B, Fig. S3C). To further evaluate the role of immobilized RGD in 
hydrogel matrices, we treated cells with both an alkylating chemotherapy and cilengitide, or 
cyclo-RGD. Cilengitide was originally developed as a targeted therapy for GBM which acts 
through selective disruption of integrin αV interaction with RGD-containing ECM proteins[30]. In 
HA-rich hydrogels with immobilized RGD peptides, addition of cilengitide competitively 
abolished the any invasive morphology (Fig. 3C; Fig. S4). While cilengitide alone did not 
significantly affect apoptosis, it had a synergistic action when combined with chemotherapy 
agents, where cl-PARP expression increased by at least 2 times (Fig. 3D, Fig. S3D). These 
results demonstrate how both HA and RGD motifs in the microenvironment can protect GBM 
cells from chemotherapy-induced apoptosis.  
3.4 Presence of HA and RGD in hydrogel matrices induce co-expression of CD44 and 
integrin αV expression in 3D-cultured GBM cells  
The RGD motif is reported to be a ligand for integrin αV, which undergoes hetero-dimerization 
with β integrin subunits upon binding[30,31]. Given that incorporation of RGD peptides into high 
HA hydrogels significantly enhanced chemotherapy resistance and that this effect was 
abolished by cilengitide treatment (Fig. 3), we posited that integrin αV, whose binding to RGD is 
selectively disrupted by cilengitide[30], and CD44 may act together to facilitate drug resistance. 
Immunostaining results indicated that GBM cells cultured within HA hydrogels bearing RGD co-
expressed CD44 and Integrin αV within close proximity (within 0.42 µm, the effective resolution 
of images captured) in cell membranes — indicating possible clustering of receptors through 
binding to the available ECM (Fig. 4). Moreover, omission of HA from hydrogels or treatment of 
cultures with cilengitide abolished co-expression of CD44 and Integrin αV (FIG. 4). Together, 
these results indicate that direct interactions between CD44 and integrin αV may mediate 
chemotherapy resistance observed in HA-RGD hydrogel cultures. 
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3.5 Integrin αV and CD44 mediate chemotherapy resistance and invasive morphology in 
3D matrices  
Next, we used lentiviral vectors encoding shRNA against CD44 or integrin αV to further 
investigate effects of their engagement on GBM cells. Interestingly, knockdown of either CD44 
or integrin αV eliminated all invasive characteristics of HK301 cells (Fig. 5A, Fig. S3E). 
However, GBM6 cells did not exhibit obvious extensions, as would be expected in invading cells 
(Fig. S5). To investigate how integrin αV affects chemotherapy-induced apoptosis, we 
compared cl-PARP expression between wildtype and integrin αV knockdown HK301 cells 
cultured in hydrogels with identical formulations. We found increased cl-PARP expression with 
integrin αV knockdown with carmustine treatment (Fig. 5B, Fig. S3F). While not statistically 
significant, a similar trend was observed with TMZ treatment. Through bioluminescence tracking 
of GBM cell growth in live cultures, the critical role of integrin αV in ECM-mediated 
chemotherapy resistance was confirmed (Fig. 5C).  
3.6 HA-CD44 and RGD-integrin αV interactions act together to promote chemotherapy 
resistance through Src signaling  
In many cancers, including GBM, Src activation is mediated by integrin binding to ECM ligands 
and can facilitate tumor cell invasion[15,32,33]. In addition, CD44-mediated activation of Src has 
been reported in colon and ovarian cancers [13,34]. Moreover, in GBM patients, Src has been 
identified as a downstream effector of EGFR signaling pathways, whose activation directly 
contributes to chemotherapy resistance[33,35]. Thus, we investigated whether CD44 and 
integrin αV downstream Src activation in GBM cells cultured in high HA hydrogels with RGD. 
With shRNA knockdown of either CD44 or integrin αV, Src phosphorylation was significantly 
reduced (Fig. 6A). Next, we confirmed that disruption of integrin-RGD binding via cilengitide 
treatment reduced Src activation (Fig. 6B).  Finally, we verified that RGD and HA were both 
required to maximize Src phosphorylation within GBM cells in 3D culture in our engineered 
matrices (Fig. 6C, D).  
Based on these results, we postulated that suppression of Src inhibition via dasatinib[16] could 
sensitize GBM cells to treatment, even in the presence of resistance-promoting matrix cues. 
First, we observed that dasatinib treatment abolished the invasive morphology of GBM cells 
(Fig. 6E; Fig. S3). Next, we found that while dasatinib alone does not induce apoptosis, dual 
treatment with an alkylating chemotherapy had a synergistic effect induced significantly more 
apoptosis (assessed by expression of cl-PARP) than treatment with either TMZ or carmustine 
alone (Fig. 6F, Fig. S3G). Consistent with these findings, dasatinib alone had no effects on 
culture growth (measured by bioluminescence imaging) while combination therapies resulted in 
a synergistic reduction in cell growth of ≥ 50% (Fig. 6G).  
3.7 HA and RGD interactions protect GBM cells from treatment-induced apoptosis 
through suppression of pro-apoptotic members of the BCL-2 family  
Src activation has been reported to regulate activities of BCL-2 family proteins, which direct 
caspase-mediated cleavage of PARP and eventually cause apoptosis[36–38]. To investigate 
the role of Src activation in GBM chemotherapy resistance, we examined expression of BCL-2 
family pro-apoptotic factors, including P53-upregulated modulator of apoptosis (PUMA), BCL-2-
associated X protein (BAX) and BCL-2 homologous antagonist killer (BAK), in all conditions. 
When treated with either alkylating chemotherapy, HK301 cells increased expression of PUMA, 
BAX, and BAK over vehicle controls (Fig. 7A, B). Dual treatment with either dasatinib or 
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cilengitide further increased this effect, while treatment with dasatinib or cilengitide alone did not 
alter the expression of any pro-apoptotic factors assayed (Fig. 7A, B). For GBM6 cells, 
treatment with either dasatinib or cilengitide alone elevated PUMA expression, while treatment 
with either alkylating chemotherapy decreased expression of all three pro-apoptotic factors (Fig. 
S6A). Notably, co-treatment with cilengitide or dasatinib rescued the expression of these pro-
apoptotic factors.  
Next, we evaluated the connection between upstream engagement of CD44 and integrin αV 
receptors by the hydrogel matrix and downstream expression of BCL-2 family pro-apoptotic 
factors in the presence of treatment. Chemotherapy treatment in cells with CD44 or integrin αV 
knockdown induced increased expression of pro-apoptotic factors (Fig. 7C, E; Fig. S6B, C). 
Even without treatment (i.e., vehicle), knockdown of either CD44 or integrin αV elevated 
expression of the pro-apoptotic factors in GBM6 cells; however, only a slight increase in 
expression of BAX and BAK occurred in HK301 cells (Fig. 7C, E). Last, we evaluated whether 
high HA content and RGD peptide were both required to suppress elevation of PUMA, BAX, and 
BAK expression with TMZ or carmustine treatment. In HK301 and GBM6 cells, the relative 
expressions of the pro-apoptotic factors when treated with either chemotherapy were consistent 
with CD44 and integrin αV knockdown results, where low HA or a lack of RGD binding sites in 
the matrix resulted in increased expression of pro-apoptotic factors (Fig. 7D, E; Fig. S6 D, E). 
Together, results demonstrate that cell-matrix interactions co-activated downstream Src to 
suppress of expression BCL-2 family pro-apoptotic factors and augment chemotherapy 
resistance.  
4. Discussion: 
The propensity of GBM to develop therapeutic resistance, where recurrence is nearly universal, 
is a critical area of study[1,39]. While molecular mechanisms leading to treatment insensitivity 
and resistance, such as MGMT methylation, have been widely investigated and despite a 
growing body of evidence suggesting a major role for ECM in resistance[40–42], few studies 
have directly evaluated the effects of CM in the microenvironment on tumor cells. Of studies 
that have explored this area, the majority have relied on adsorbing purified ECM biomolecules 
onto hard, 2D surfaces, such as glass or tissue-culture plastic[40], or have added ECM 
components that do not readily adsorb, such as HA, directly to culture medium in a non-
physiological, soluble form[13].  However, these methods fail to recapitulate key aspects of the 
tumor ECM, which is a soft, HA-rich, microporous scaffold in which cells are embedded in three 
dimensions. Recent studies have demonstrated that bioengineered, 3D culture systems, 
designed to mimic the native brain tumor ECM, can be used to study the therapeutic response 
of GBM cells ex vivo in a context that yields resistant phenotypes more similar to those 
observed in vivo than can be achieved using traditional, 2D cultures[43–48]. While the focus of 
the majority of previous studies has been to demonstrate feasibility and potential utility of such 
3D culture platforms, here we have applied a bioengineered culture platform to elucidate 
detailed mechanisms of ECM-mediated treatment resistance in patient-derived GBM cells.  
Here, we used a tunable, bioengineered culture platform 1) to demonstrate that the 3D 
microenvironment provided by the ECM facilitates acquisition of drug resistance in GBM and 2) 
to elucidate mechanisms underlying this phenomenon. Through parallel experiments where 
either HA was removed from the extracellular milieu or CD44 expression was knocked down, 
results demonstrate that HA-CD44 interactions promote cytostatic and cytotoxic resistance to 
treatment with carmustine or TMZ. In particular, resistance was robust compared to patient-
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matched GS cultures, which we have previously shown do not express high levels of HA[21], 
underscoring the critical contributions of the local ECM microenvironment to GBM cell biology. 
Moreover, our results indicate that HA may promote GBM cell survival during treatment, 
allowing cells to recover during periods of “rest” from treatment, similar to a typical 
chemotherapy cycle in a clinical setting. Specifically, scaffolds with high HA content protected 
GBM cells from chemotherapy-induced apoptosis. HA may have a similar protective effect in 
clinical GBM, where increased HA expression positively correlates with tumor aggression 
[10,17],  
Furthermore, we incorporated the integrin-binding, RGD tripeptide into HA hydrogel scaffolds to 
mimic interactions between cells and ECM proteins, many of which have been implicated in 
GBM aggression (e.g., collagen[49], fibronectin[50], and vitronectin[41]) and contain the RGD 
motif through which they can interact with integrin receptors[51]. An important design feature of 
the hydrogel scaffolds used here is that HA and RGD content can be varied independently of 
culture dimensionality, mechanical properties, and diffusivity[48]. Given that both integrin and 
CD44 receptors are mechano-responsive[8,20] and that mechanical properties of the 3D 
microenvironment have strong effects on treatment resistance in GBM[21,52], hydrogel 
mechanical properties were kept constant around 150 Pa (shear elastic modulus). Previously, 
we demonstrated that HA-rich hydrogels with this modulus maximized the ability of GBM cells to 
acquire resistance to targeted EGFR inhibition[21]. The differential effects of RGD when 
immobilized to insoluble hydrogel scaffolds, compared to when added as soluble cyclo-RGD 
(i.e., cilengitide), also provided evidence of force transduction from the matrix. Specifically, while 
immobilized RGD promoted resistance and an invasive morphology, these effects were 
reversed by addition of soluble RGD. 
Consistent with our previous findings[21], increasing HA content in bioengineered matrices 
correlated with GBM cell upregulation in expression of the HA receptor CD44. Here, we 
demonstrate that engagement of CD44 and/or integrin αV induces downstream Src 
phosphorylation. In turn, activated Src suppressed expression of the BCL-2 family of pro-
apoptotic factors in response to chemotherapies. When treated with alkylating chemotherapies 
— which function by damaging the DNA of rapidly dividing cells, such as cancer cells, to 
activate downstream apoptosis — this effect was more pronounced. Previous studies have 
reported that depressed apoptotic signaling in cancer cells may allow the cell to stay alive 
during an “intermediate” period over which they acquire resistance to treatment through other 
mechanisms, including repair of alkylated DNA through DNA mismatch repair (MMR) complexes 
and upregulation of drug efflux pumps such as p-glycoprotein[39]. Notably, we report the novel 
finding that ECM engagement rescues GBM cells from chemotherapy-induced apoptosis, 
potentially through suppression pro-apoptotic factors downstream of the P53 signaling pathway 
such as PUMA. This result suggests that treatment with a p53 activator, such as nutlin[25], in 
combination with alkylating chemotherapies may counteract the pro-survival actions of the 
tumor ECM.  
Here, we found that addition of RGD to HA matrices reduced chemotherapy-induced apoptosis 
by around 50% (Fig. 3B) — consistent with previous findings in glioma and lung cancer 
models[41,42]. Furthermore, dual treatment of either chemotherapy with cilengitide, to disrupt 
integrin-RGD binding, resulted in around three-fold increase in cl-PARP expression over 
chemotherapy alone (Fig. 3D). We posit two potential explanations for these findings. First, it is 
likely that GBM cells deposited additional integrin-binding ECM proteins during the culture 
period and that cilengitide treatment inhibited these interactions as well as those with hydrogel-
immobilized RGD, resulting in higher level of apoptosis. Second, disruption of integrin-RGD 
interactions may have interfered with chemo-protection provided by CD44-HA interactions, 
indicating the possibility of cooperative effects of CD44 and integrin αV signaling.  
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Observations of co-expression (Fig. 4) and systematic knockdowns (Fig. 5) of CD44 and 
integrin αV provided additional evidence that engagement of these two receptors within a 3D 
matrix acts cooperatively to protect GBM cells from drug-induced apoptosis. These results are 
in agreement with previous reports indicating that CD44 and integrins can physically interact at 
the cell membrane[6,34]. Furthermore, our results demonstrate that engagement of CD44 and 
integrin αV receptors amplified downstream activation of Src to suppress treatment-induced 
apoptosis (Figs. 6, 7). Previously, Src activation has been linked to integrin activation and 
invasive morphology[13,15,32], as well as survival and chemotherapy resistance[14,53], in 
various cancer types . However, to the best of our knowledge, this is the first report 
demonstrating a direct connection between interactions of CD44 and integrins with the 3D ECM 
leading to Src activation and downstream phenotypic changes in GBM cells. Our previous study 
demonstrated that HA and RGD present in 3D culture matrices could promote development of 
resistance to inhibition of using targeted treatments[21]. In this study, we revealed how the 
same matrix microenvironment intensifies Src activation, which others have reported to mediate 
resistance to EGFR inhibition via lapatinib in breast cancer[54]. Thus, we suspect that GBM 
may also be escape EGFR inhibition through matrix-mediated activation of Src. 
While a previous phase II clinical trial (NCT00813943) found that addition of the integrin inhibitor 
cilengitide to radio- and chemotherapy improved median overall survival improved to 16.3 
months from 13.4 months, the phase III trial did not find any improved outcomes (NCT00689221) 
[55,56]. Given our results showing the contribution of the non-integrin CD44 receptor to 
chemotherapy resistance, addition of therapies targeting the downstream signaling molecules of 
matrix-mediated resistance, such as Src, may be more beneficial. Although previous work has 
identified Src inhibition via dasatinib as a possibly effective monotherapy for treatment of GBM 
using standard, 2D cell culture experimental set-up[16], phase I/II clinical trials evaluating 
dasatinib for treatment of recurrent GBM found that dasatinib monotherapy was ineffective 
(NCT00423735)[57]. This result is consistent with our finding in 3D hydrogel cultures, where the 
response of GBM cells to dasatinib treatment alone was equivalent to vehicle controls (Fig. 
6F,G), indicating that our novel hydrogel platform may be a better tool for in vitro, pre-clinical 
screening evaluation of therapeutic strategies than 2D culture methods. While dasatinib was not 
effective as a monotherapy, our results do indicate that dual treatment with dasatinib and 
chemotherapy may be effective. There has been one phase II clinical study that investigated the 
use of dasatinib treatment after the conclusion of more routine radiation and chemotherapy 
(TMZ) treatment in newly diagnosed GBM patients (NCT00869401). However, this study did not 
find any benefits of adding dasatinib over routine therapy alone. Our results indicate that 
dasatinib may only be effective if given in conjunction with, or even prior to, TMZ to inhibit Src 
activation and promote apoptosis. However, one cannot exclude other factors, such as 
inefficient penetration of dasatinib into patient tumors, as possible contributors to the clinical 
failure of dasatinib in GBM [58].  
In conclusion, we report the use of a bioengineered, 3D culture platform to elucidate 
mechanisms underlying ECM-mediated chemotherapy resistance in patient-derived GBM cells. 
Our results demonstrate how matrix engagement of CD44 and integrin αV augments 
downstream Src activation, causing depression of BCL-2 family pro-apoptotic factors. This 
finding provides a strong rationale for investigating the efficacy of simultaneous treatment with 
Src inhibitors and TMZ in future studies. 
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Figure Captions 
Figure 1. High HA content hydrogels facilitate chemotherapy resistance. A) Schematic of 
12-day chemotherapy treatment regimen consisting of 2 cycles of 3 days of treatment followed 
by 3 days of “rest”. Drug treatments included carmustine, temozolomide (TMZ), or vehicle 
(ethanol for carmustine, DMSO for TMZ). B) Representative phase contrast image of HK301 
cells cultured in 3D scaffolds with low (0.1% w/v) or high (0.5% w/v) hyaluronic acid (HA) after 
the 12-day drug treatment. Scale bars = 200 µm. C) Representative bioluminescence 
measurements (single biological repeat shown) of HK301 cells over 12 days of treatment. 
Relative luminescence units (RLU) was normalized for background and measurement area. 
Within each condition, normalized RLU of treated samples were normalized to vehicle controls 
at each time point, then to signal before treatment (day 0). Two-way ANOVA (culture condition, 
time) was performed. Error bars show standard deviations (n=3). D) Bioluminescence signal in 
treated cultures of HK301 and GBM6 cells normalized to vehicle controls at the end of the 12-
day chemotherapy regimen (n=3). One-way ANOVA followed by Tukey’s multiple comparison 
tests were performed. Error bars show standard deviations. *p<0.5, **p<0.01, ***p<0.001, 
****p<0.0001, “ns” represents non-significance. 
 
Figure 2. Hyaluronic acid (HA) in 3D matrices interacts with CD44 to protect against 
chemotherapy-induced apoptosis. A) Representative flow cytometry plots showing EdU+ 
GBM6 cells (EdU incorporation by cells undergoing division, through S-phase, during a 2.5 hr 
incubation) after 3 days of carmustine treatment (100 µM). B) Representative Western blots 
showing cl-PARP expression in HK301 cells cultured in high HA (0.5% w/v) matrices or as 
gliomaspheres (GS) after 3 days of carmustine (50 µM) or TMZ (500 µM) treatment. C) Left 
panel: Representative Western blots showing cl-PARP expression in GBM6 cells cultured in 
matrices with low (0.1 w/v) or high (0.5% w/v) HA after 3 days of treatment with carmustine 
(Carm., 100 µM), temozolomide (TMZ, 500 µM), or vehicle. Right panel: Densitometry analysis 
of Western blots, cl-PARP normalized to GAPDH, across independent repeats (n=3). D) Left 
panel: Representative Western blots showing cl-PARP expression in GBM6 cells (wildtype and 
shRNA knockdown of CD44) cultured in high HA matrices after 3 days of treatment with 
carmustine (Carm., 100 µM), temozolomide (TMZ, 500 µM), or vehicle. Right panel: 
Densitometry analysis of Western blots, cl-PARP normalized to GAPDH, across independent 
repeats (n=3). C, D) Error bars show standard deviations. A student’s t test was used to 
compare cl-PARP expression within each treatment arm. *p<0.5, **p<0.01, ***p<0.001, 
****p<0.0001, “ns” represents non-significance. 
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Figure 3. Hyaluronic acid (HA) and RGD synergistically protect against treatment-induced 
apoptosis. A) Representative phase contrast images of HK301 cells cultured for 8 days in 
hydrogels with high HA (0.5% w/v) and either adhesive peptides bearing the RGD motif or non-
adhesive cysteines (“CYS”) as a negative control. Arrows indicate cells displaying invasive 
morphologies. Scale bars = 200 µm. B) Upper panel: Representative Western blots showing cl-
PARP expression in HK301 cells, cultured in high HA matrices containing RGD (or CYS control) 
peptides, after 3 days of treatment with carmustine (Carm., 50 µM), temozolomide (TMZ, 500 
µM), or vehicle. Lower panel: Densitometry analysis of Western blots, cl-PARP normalized to 
GAPDH, across independent repeats (n=3). C) Representative phase contrast images of HK301 
cells cultured in 3D hydrogel matrices with high HA and RGD after 4 days after cilengitide 
treatment (50 µM). Cells were cultured for 8 days in hydrogels before starting cilengitide 
treatment. Arrows indicate cells displaying invasive morphologies. Scale bars = 200 µm. D) 
Upper panel: Representative Western blots showing cl-PARP expression in GBM6 cells cultured 
in 3D hydrogel matrices with high HA and RGD after 3 days of treatment with carmustine (Carm., 
100 µM), temozolomide (TMZ, 500 µM), or vehicle. Cilengitide treatment (50 µM) was started 4 
days before beginning chemotherapy treatment. Lower panel: Densitometry analysis of Western 
blots, cl-PARP normalized to GAPDH, across independent repeats (n=3). Two-way ANOVA 
(cilengitide, chemotherapy) was performed. pint= 0.03 for HK301 and pint=0.005 for GBM6. Error 
bars show standard deviations. A student’s t-test was used to compare cl-PARP expression 
within each treatment arm. *p<0.5, **p<0.01, ***p<0.001, ****p<0.0001, “ns” represents non-
significance. 
 
Figure 4.  CD44 and Integrin αV are co-expressed by GBM cells cultured in 3D matrices 
containing both hyaluronic acid (HA) and RGD peptides. Representative fluorescence 
images of immunostaining for CD44 (red) and integrin αV (green) of GBM6 and HK301 cells 
cultured in high HA matrices containing RGD (or CYS control) peptide for 8 days. Nuclei were 
counterstained with Hoescht 33342 (blue). Primary antibody was omitted for negative control 
images. Arrows indicate areas of CD44 and integrin αV co-expression (yellow). Cells were 
cultured 8 days before cilengitide treatment (50 µM), which continued for 3 days. Scale bars = 
200 µm (20 µm for magnified insets of areas shown by white boxes). 
 
Figure 5. Integrin αV and CD44 mediate both chemotherapy resistance and invasive 
morphology cultured in 3D matrices including hyaluronic acid (HA) and RGD motifs. A) 
Representative phase contrast images of HK301 cells (wildtype and shRNA knockdowns of 
CD44 and/or integrin αV (ITGAV)) cultured for 8 days in hydrogels with high HA and RGD. 
Arrows indicate cells displaying invasive morphologies. Areas indicated by white boxes in the 
top row of images are shown at higher magnification in the bottom row. Scale bars = 200 µm. B) 
Left panel: Representative Western blots showing cl-PARP expression in HK301 cells (wildtype 
and shRNA knockdown of ITGAV) cultured in hydrogels with high HA and RGD after 3 days of 
treatment with with carmustine (Carm., 50 µM), temozolomide (TMZ, 500 µM), or vehicle. Right 
panel: Densitometry analysis of Western blots, cl-PARP normalized to GAPDH, across 
independent repeats (n=3). A student’s t test was performed to compare cl-PARP expression 
within each treatment arm. Error bars show standard deviations. C) Left panel: Representative 
bioluminescence signal overlaid with a photograph of HK301 cultures on the 12th day 12 of 
chemotherapy treatment regimen. Red circles indicate locations of hydrogel cultures with the 
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well plate. Right panel: Bioluminescence signal (RLU – Relative Luminescence Units) in treated 
cultures of HK301 cells normalized to vehicle controls at the end of the 12-day chemotherapy 
regimen (n=3). One-way ANOVA with Tukey’s multiple comparison tests was performed. Error 
bars show standard deviations. ****p<0.0001. 
 
Figure 6. HA-CD44 and RGD-integrin αV interactions promote chemotherapy resistance 
through Src signaling. A-D) Representative Western blots showing Src phosphorylation in 
GBM cells (HK301, GBM6, GS024, GS025 lines). For A, C and D, cell lysates were collected 
after 8 days in 3D culture. For B, cilengitide (50 µM) treatment was started on day 8 of culture 
and cell lysates were collected after 3 days of treatment. Densitometry analysis showing the 
ratio of p-SRC to t-SRC is indicated within each panel. E) Representative phase contrast 
images of HK301 cells cultured in hydrogel matrices with high HA (0.5% v/w) and RGD for 4 
days, then treated for 4 days with dasatinib (100 nM) or vehicle (DMSO). Arrows show cells 
displaying invasive morphologies. Scale bars = 200 µm. F) Upper panel: Representative 
Western blots showing Src phosphorylation in GBM6 after 3 days of treatment with carmustine 
(Carm., 100 µM), temozolomide (TMZ, 500 µM), or vehicle. Dasatinib (100 nM) or vehicle 
(DMSO) was started 4 days before adding chemotherapy treatment. Lower panel: Densitometry 
analysis of Western blots, cl-PARP normalized to GAPDH, across independent repeats (n=3). 
Student’s t test was performed to compare cl-PARP expression within each treatment arm. Error 
bars show standard deviations. Two-way ANOVA (dasatinib, chemotherapy) was performed. 
pint= 0.003 for HK301 and pint=0.0002 for GBM6.  G) Left panel: Representative 
bioluminescence signal overlaid with a photograph of HK301 cultures on the 12th day 12 of 
chemotherapy treatment regimen. Red circles indicate locations of hydrogel cultures with the 
well plate. Right panel: Bioluminescence signal in treated cultures of HK301 cells normalized to 
vehicle controls at the end of the 12-day chemotherapy regimen (n=3). Two-way ANOVA 
(dasatinib, chemotherapy) was performed. pint= 0.03.  Error bars show standard deviations. 
*p<0.5, **p<0.01, ***p<0.001, ****p<0.0001, “ns” represents non-significance. 
 
Figure 7. Hydrogel matrices containing HA and RGD adhesive peptides protect 3D-
cultured GBM cells from drug-induced apoptosis through suppression of PUMA, BAK 
and BAX. A-E) Representative Western blots showing expression of BCL-2 family factors, 
PUMA, BAK and BAX, in HK301 cells. For A-D, cells were culture in 0.5% HA (w/v) hydrogels 
with RGD peptides. For E, no RGD was added to hydrogels. Blots were performed on cell 
lysates collected after 3 days of treatment with chemotherapy or vehicle. Densitometry analysis 
of integrated band intensities normalized to GAPDH is indicated in each panel. Please see 
Figure S7 for statistical summarization of the western blotting experiments.  
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Highlights: 
Hyaluronic acid (HA) and RGD-containing proteins in the extracellular matrix (ECM) interact with 
integrin and CD44 receptors, respectively, on patient-derived glioblastoma (GBM) cells to 
promote upregulation of Src in novel 3D hydrogel cultures. 
Matrix-mediated Src activation promotes invasive morphologies and deregulates expression of 
pro-apoptotic factors induced by chemotherapies in GBM. 
HA and adhesive proteins in the ECM protect GBM cells from chemotherapy-induced apoptosis.  
Combinatorial treatment with chemotherapy dasatinib, which inhibits Src phosphorylation, 
provides a promising strategy to overcome matrix mediated drug resistance in GBM. 
ACCEPTED MANUSCRIPT
